Here are some sample widgets you could interact with from this dashboard:
Abbott's stock is down by about -14% compared to about -22% for Medtronic since early February. The current coronavirus crisis will likely impact medical devices company on two fronts, 1. supply chain disruptions, and 2. decline in number of procedures performed. On the positive side, medical devices companies are also developing new tests for Covid-19. Abbott in particular received FDA approval last week for its 5-minute Covid-19 test. This will help Abbott offset revenue decline, if any, from decline in procedures and supply disruptions in the near term. Abbott is ramping up production to deliver 50,000 tests per day. On the other hand, Medtronic also launched products to monitor patients for Covid-19. These factors also explain the outperformance of Abbott compared to the S&P 500, which is down 21% since early February. Below, we take a look at whether Abbott could be a better bet compared to Medtronic by looking at its fundamental performance.
CORONAVIRUS CRISIS : Since early February Abbott Laboratories stock has moved -14.4% compared to -21.6% for the Medtronic.Abbott's stock has declined by about 14% since early February, compared to 22% for Medtronic, after the WHO declared a global health emergency relating to Coronavirus.Abbott and Medtronic's stocks have fallen by about 9% since March 8th, as U.S. cases accelerated.
Abbott Laboratories% Change For Key Dates: 2020 Crisis
Medtronic% Change For Key Dates: 2020 Crisis
HISTORICAL PERFORMANCE: From 2009-2019 Abbott Laboratories stock has grown at 1.5x the rate of the Medtronic
Abbott Laboratories stock went from $20.21 at the end of 2009 to $86.49 at the end of 2019, representing a change of 328%.
During the same time period, Medtronic went from $34.93 to $112.74 representing a change of 222.8%.
This implies that Abbott Laboratories stock grew at 1.5x the rate of Medtronic.
ABT Stock Price
MDT Stock Price
ABT Stock Price Annualized Rate of Return
MDT Stock Price Annualized Rate of Return
ANALYSIS: Is Abbott Laboratories stock expensive based on a review of the fundamentals?
P/E Ratio: Based on trailing 2019 P/E ratios, ABT stock looks attractive compared to prior years and expensive compared to Medtronic
Abbott's current P/E multiple (based on 2019 results) stands at about 33x, compared to about 22x for Medtronic.
* P/E Ratio is calculated based on year end market price and trailing earnings. However, for 2020 P/E, we use 2019 earnings and current market price.
Historical Revenue Growth: Abbott's revenue growth over the last 6 years was slightly lower than Medtronic's
Abbott's 2014-19 annualized revenue growth of 10% compares with the 2014-19 annualized revenue growth rate of 13% for Medtronic.
2014-19 Annualized Revenue Growth Comparison
Abbott's Revenue Growth
Medtronic's Revenue Growth
Historical EPS Growth: Abbott's EPS growth was much higher than Medtronic's
Abbott's 2014-19 annualized EPS growth of 107% is 18x that of the 2014-19 annualized EPS growth rate of 6% for Medtronic.
2014-19 Annualized EPS Growth Comparison
Abbott's EPS Growth
Medtronic's EPS Growth
Survival Check: Total Debt Comparisons
Abbott Laboratories Total Debt increased from $8 billion in 2014 to $28 billion in 2017, but declined thereafter to $18 billion in 2019. In comparison, Total Debt for Medtronic grew from $12 billion in 2014 to $33 billion in 2017, and it declined to $25 billion in 2019.
Abbott's Total Debt
Medtronic's Total Debt